Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-label, Phase II Study With a Safety Lead-in Part Investigating the Efficacy, Safety and Pharmacokinetics of Encorafenib and Binimetinib Combination in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer Who Are BRAF- and MEK Inhibitor Treatment-naïve

NCT05195632 is registered in ClinicalTrials.gov with Pierre Fabre Medicament as lead sponsor.

NCT NCT05195632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05195632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-label, Phase II Study With a Safety Lead-in Part Investigating the Efficacy, Safety and Pharmacokinetics of Encorafenib and Binimetinib Combination in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer Who Are BRAF- and MEK Inhibitor Treatment-naïve
Lead sponsor
Pierre Fabre Medicament
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 2, 2022
Completion date
December 14, 2026
Enrollment
63 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer